Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Toxicity Conditioning for Wiskott-Aldrich Syndrome
NCT00885833Phase 2Completed
- Sponsor
- Korean Society of Pediatric Hematology-Oncology
- Start
- Feb 2007
- Primary completion
- Mar 2012
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, busulfan and antithymocyte globulin in Wiskott-Aldrich syndrome (WAS), sponsored by Korean Society of Pediatric Hematology-Oncology. Primary endpoints: Engraftment potential at 5 years, Incidence and severity of toxicity at 5 years and 1 more. Started Feb 2007; status: completed.
02
Drugs
fludarabinebusulfanantithymocyte globulin
03
Conditions
Wiskott-Aldrich syndrome (WAS)
Beyond the preview
Go deeper on NCT00885833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885833.